Ahmed D, Vander Ende K, Harvey P, et al. 2022 Human papillomavirus (HPV) vaccine introduction in Sikkim state: best practices from the first statewide multiple-age cohort HPV vaccine introduction in India 2018–2019. Vaccine 40 A17–A25

Article  PubMed  Google Scholar 

Almeida AM, Queiroz JA, Sousa F, et al. 2019 Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discov. Today 24 2044–2057

Article  PubMed  CAS  Google Scholar 

Amponsah-Dacosta E, Blose N, Nkwinika VV, et al. 2022 Human papillomavirus vaccination in South Africa: programmatic challenges and opportunities for integration with other adolescent health services? Front. Public Health 10 799984

Article  PubMed  PubMed Central  Google Scholar 

Araldi RP, Assaf SMR, de Carvalho RF, et al. 2017 Papillomaviruses: a systematic review. Genet. Mol. Biol. 40 1–21

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arbyn M, Tommasino M, Depuydt C, et al. 2014 Are 20 human papillomavirus types causing cervical cancer? J. Pathol. 234 431–435

Article  PubMed  CAS  Google Scholar 

Arroyo Muhr LS, Eklund C, and Dillner J 2021 Misclassifications in human papillomavirus databases. Virology 558 57–66

Bagarazzi ML, Yan J, Morrow MP, et al. 2012 Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci. Transl. Med. 4 155ra138

Bachmann MF, Rohrer UH, Kundig TM, et al. 1993 The influence of antigen organization on B cell responsiveness. Science 262 1448–1451

Basu P, Malvi SG, Joshi S, et al. 2021 Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 22 1518–1529

Article  PubMed  PubMed Central  CAS  Google Scholar 

Berzofsky JA, Ahlers JD, Janik J, et al. 2004 Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 114 450–462

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bolhassani A, Mohit E and Rafati SR 2009 Different spectra of therapeutic vaccine development against HPV infections. Hum. Vaccin. 5 671–689

Article  PubMed  CAS  Google Scholar 

Bruni L, Saura-Lázaro A, Montoliu A, et al. 2021 HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev. Med. 144 106399

Article  PubMed  Google Scholar 

Burd EM 2003 Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16 1–17

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burki TK 2023 India rolls out HPV vaccination. Lancet Oncol. 24 e147

Article  PubMed  Google Scholar 

Cates W 1999 Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex. Transm. Dis. 26 S2–S7

Article  PubMed  Google Scholar 

CDC 2021 HPV vaccine safety (https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html)

CDC 2024 Cancers associated with human papillomavirus (https://www.cdc.gov/united-states-cancerstatistics/publications/hpv-associated-cancers.html)

Choudhury P and Yewale V 2011 Human papilloma virus vaccines and current controversy reply. Indian Pediatr. 48 248–249

Google Scholar 

Coughlan L, Kremer EJ and Shayakhmetov DM 2022 Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens. Mol. Ther. 30 1822–1849

Article  PubMed  PubMed Central  CAS  Google Scholar 

De Bruijn ML, Greenstone HL, Vermeulen H, et al. 1998 L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250 371–376

Article  PubMed  Google Scholar 

de Martel C, Georges D, Bray F, et al. 2020 Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8 e180–e190

Article  PubMed  Google Scholar 

Dillner J, Arbyn M, Unger E, et al. 2011 Monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 163 17–25

Article  PubMed  PubMed Central  CAS  Google Scholar 

Draper E, Bissett SL, Howell-Jones R, et al. 2013 A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) human papillomavirus vaccines in 12-15 year old girls. PLoS One 8 e61825

Dubensky TW and Reed SG 2010 Adjuvants for cancer vaccines. Semin. Immunol. 22 155–161

Article  PubMed  CAS  Google Scholar 

Dürst M, Gissmann L, Ikenberg H, et al. 1983 A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. USA 80 3812–3815

Article  PubMed  PubMed Central  Google Scholar 

Esquerré M, Bouillette-Marussig M, Goubier A, et al. 2017 GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression. PLoS One 12 e0174038

Article  PubMed  PubMed Central  Google Scholar 

Gandhapudi SK, Ward M, Bush JPC, et al. 2019 Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J. Immunol. 202 3524–3536

Article  PubMed  CAS  Google Scholar 

Gold D 2012 The psychosocial care needs of patients with HPV-related head and neck cancer. Otolaryngol. Clin. North Am. 45 879–897

Article  PubMed  Google Scholar 

Guidotti LG and Chisari FV 2001 Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19 65–91

Article  PubMed  CAS  Google Scholar 

Hamley IW 2022 Peptides for vaccine development. ACS Appl. Bio. Mater. 5 905

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hancock G, Hellner K and Dorrell L 2018 Therapeutic HPV vaccines. Best. Pract. Res. Clin. Obstet. Gynaecol. 47 59–72

Article  PubMed  Google Scholar 

Harro CD, Pang YY, Roden RB, et al. 2001 Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer. Inst. 93 284–292

Article  PubMed  CAS  Google Scholar 

Hausen HZ 2002 Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 342–350

Article  PubMed  Google Scholar 

Howard N, Mounier-Jack S, Gallagher KE, et al. 2016 The value of demonstration projects for new interventions: the case of human papillomavirus vaccine introduction in low- and middle-income countries. Hum. Vaccines Immunother. 12 2475–2477

Article  CAS  Google Scholar 

Huang CM 2008 Human papillomavirus and vaccination. Mayo. Clin. Proc. 83 701–706

Article  PubMed  Google Scholar 

Huh WK, Joura EA, Giuliano AR, et al. 2017 Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 390 2143–2159

Article  PubMed  CAS  Google Scholar 

Ikeda Y, Uemura Y, Asai-Sato M, et al. 2019 Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized placebo-controlled clinical trial (MILACLE study). Jpn. J. Clin. Oncol. 49 877–880

Article  PubMed  Google Scholar 

Indian Academy of Pediatrics Committee on Immunization (IAPCOI) 2008 Consensus recommendations on immunization, 2008. Indian Pediatr. 45 635–648